StockNews.AI
REPL
StockNews.AI
20 days

REPL Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Securities Fraud Class Action Involving Replimune Group, Inc.

1. Class action filed against Replimune for misleading investors on IGNYTE trial viability. 2. Replimune's IGNYTE trial deemed inadequate by FDA, affecting stock value. 3. REPL's stock dropped 77.24% on July 22, 2025, following negative news. 4. Investors may participate in class action lawsuit concerning losses incurred. 5. Robbins LLP is leading the class action to protect shareholder rights.

6m saved
Insight
Article

FAQ

Why Very Bearish?

The negative FDA response severely impacts investor confidence and company valuation, as seen with similar cases in biotech firms. For example, stocks like Axovant Gene Therapies dropped significantly post-negative trial news.

How important is it?

The class action directly addresses significant allegations against Replimune, impacting stock perception and market trust. This is crucial for existing and prospective investors.

Why Short Term?

Immediate reaction seen in stock price indicates that investor sentiment is currently very negative. Similar past events have typically resulted in short-lived but strong stock depreciation.

Related Companies

AXGTPTCTCRSP
, /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024 and July 21, 2025. Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.  For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Replimune Group, Inc. (REPL) Misled Investors Regarding the Viability of its IGNYTE Trial   According to the complaint, during the class period defendants failed to disclose that: (1) defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants' statements about Replimune's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Plaintiff alleges that on July 22, 2025, Replimune announced that it had received a complete response letter ("CRL") from the FDA for RPI Biologics License Application for the treatment of advanced melanoma and that the CRL "indicates that the FDA is unable to approve the application in its present form because the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness. On this news, the price of Replimune stock plummeted by $9.52 per share, or 77.24%, to close at $2.80 per share on July 22, 2025. What Now: You may be eligible to participate in the class action against Replimune Group, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by September 22, 2025. Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.  You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.  About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.  To be notified if a class action against Replimune Group, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. www.robbinsllp.com SOURCE Robbins LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News